← All candidates
No insider filings on record.
7 filings on record.
TRAXFirst Tracks Biotherapeutics, Inc.
NasdaqGS · Healthcare · $1.37B
$38.47
+2.40% · Sep 15
No insider filings on record.
First Tracks Biotherapeutics, Inc. hasn't reported Form 4 activity yet.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.37B
Float
26.2M
73% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
No insider transactions on file for TRAX yet.
Context
Wall St
$69.44 avg target
+80.5% vs today · 9 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 1 quarters beat
Q2 '26−$0.95 act−$0.15
Coverage
TRAX Stock Hits All-Time High — What's Driving The Super Rally?Stocktwits · 07-10How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst TargetsSimply Wall St. · 05-15AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million SharesMT Newswires · 03-27Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?Insider Monkey · 05-10
The file stays open
7 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice